Results 181 to 190 of about 54,603 (242)

Bibliometric visualization of hepatocellular carcinoma and metabolic syndrome research: trends and emerging areas. [PDF]

Discov Oncol
Chen K, Feng Q, Liu H.
europepmc   +1 more source

Rifaximin‐α in Patients With Recurrent Episodes of Hepatic Encephalopathy Due to Cirrhosis Reduces Healthcare Utilization

United European Gastroenterology Journal, EarlyView.
ABSTRACT Background and Aims Hepatic encephalopathy is a frequent complication of cirrhosis. Rifaximin‐α has been included in guidelines for secondary prevention of hepatic encephalopathy, but there are few real‐world data on its efficacy and impact on healthcare utilization.
Diederick J. van Doorn, Kirsi. M. A. van Eekhout, Koos de Wit, L. C. Baak, Michael Klemt‐Kropp, Bart J. Verwer, Philip Friederich, Gijs J. de Bruin, Xander G. Vos, Joost P. H. Drenth, R. Bart Takkenberg   +10 more
wiley   +1 more source

Research progress on the roles of complement in liver injury. [PDF]

World J Hepatol
Ou LL, Jiang JL, Guo ML, Wu JH, Zhong WW, He YH.   +5 more
europepmc   +1 more source

Minimal Hepatic Encephalopathy in Cirrhotic Patients: A New Simple and Fast Digital Screening Method

United European Gastroenterology Journal, EarlyView.
ABSTRACT Backround Minimal hepatic encephalopathy is a common and prognostically severe complication of cirrhosis with a significant impact on the quality of life. Detailed diagnostic work‐up of minimal hepatic encephalopathy is time‐consuming and difficult to integrate into daily clinical routine.
Henrike Dobbermann, Raffael Schlüter, Yevgeniy Lyubchenko, Johanna Beder, Sven Danneberg, Katharina Mitzlaff, Iris Engelbart, Jakob Jessberger, Felix Braun, Thomas Becker, Christian Labenz, Monique Janneck, Denys Matthies, Friedhelm Sayk, Jens U. Marquardt   +14 more
wiley   +1 more source

Gut microbiota in liver diseases: initiation, development and therapy. [PDF]

Front Med (Lausanne)
Yu JX, Wu J, Chen X, Zang SG, Li XB, Wu LP, Xuan SH.   +6 more
europepmc   +1 more source

Diagnosis and Monitoring Pathways Using Non‐Invasive Tests in Patients With Alpha‐1 Antitrypsin Deficiency‐Associated Liver Disease: Results From an Expert Delphi Panel

United European Gastroenterology Journal, EarlyView.
ABSTRACT Background and Aims The severe alpha‐1 antitrypsin deficiency (AATD) genotype Pi*ZZ increases the risk of liver disease (AATD‐LD) and lung disease. While non‐invasive tests (NITs) are widely used for fibrosis stage and monitoring of all liver diseases, the consensus for use in AATD‐LD is limited.
Virginia C. Clark, Mark A. Price, Jon Russo, Rohit Loomba, Alice M. Turner, Pavel Strnad   +5 more
wiley   +1 more source

European Consensus on Malabsorption—UEG & SIGE, LGA, SPG, SRGH, CGS, ESPCG, EAGEN, ESPEN, and ESPGHAN

United European Gastroenterology Journal, EarlyView.
ABSTRACT Malabsorption is a complex and multifaceted condition characterised by the defective passage of nutrients into the blood and lymphatic streams. Several congenital or acquired disorders may cause either selective or global malabsorption in both children and adults, such as cystic fibrosis, exocrine pancreatic insufficiency (EPI), coeliac ...
Marco Vincenzo Lenti, Heinz Florian Hammer, Ilja Tacheci, Rosa Burgos, Stephane Schneider, Anastasiou Foteini, Aleksejs Derovs, Jutta Keller, Ilse Broekaert, Marianna Arvanitakis, Dan Lucian Dumitrascu, Oscar Segarra‐Cantón, Željko Krznarić, Juris Pokrotnieks, Gonçalo Nunes, Johann Hammer, Loris Pironi, Marc Sonyi, Cristina Maria Sabo, Juan Mendive, Adrien Nicolau, Jernej Dolinsek, Denisa Kyselova, Lucrezia Laterza, Antonio Gasbarrini, Teodora Surdea‐Blaga, Jorge Fonseca, Christos Lionis, Gino Roberto Corazza, Antonio Di Sabatino   +29 more
wiley   +1 more source

Research Progress on the Protective Effect of Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate (EGCG) on the Liver. [PDF]

Nutrients
Zhou F, Deng S, Luo Y, Liu Z, Liu C.
europepmc   +1 more source

Key Predictors of Relevant Weight Loss in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease

United European Gastroenterology Journal, EarlyView.
ABSTRACT Background and Aims Weight loss is an effective therapeutic strategy for patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). This study aimed to identify factors that predict relevant weight loss, defined as at least 7% of initial body weight, in MASLD outpatients.
Nicola Pugliese, Ivan Arcari, Federica Cerini, Rosa Lombardi, Federica Turati, Grazia Pennisi, Matteo Soleri, Simone Rocchetto, Diletta De Deo, Michele Sagasta, Chiara Masetti, Anna Ludovica Fracanzani, Salvatore Petta, Carlo La Vecchia, Mauro Viganò, Alessio Aghemo   +15 more
wiley   +1 more source

Bacterial Infections in Patients With Severe Alcohol-Associated Hepatitis: Drivers of Organ Failure and Mortality. [PDF]

Liver Int
Buttler L, Stange J, Pyrsopoulos N, Hassanein T, Wedemeyer H, Maasoumy B, Busch M, VTL‐308 study group.   +7 more
europepmc   +1 more source